Full Press Release Details
Reports First Quarter 2026 Financial Results and Highlights Smell AI Execution Across Semiconductors and Healthcare Infrastructure Markets
TX / ACCESS Newswire / May 13, 2026 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos" or the "Company") today announced
financial results for the first quarter ended March 31, 2026 and provided a business update on recent execution progress for AI Nose
across semiconductors and healthcare infrastructure applications.
the first quarter of 2026, Ainos continued executing its commercialization priorities for AI Nose across industrial infrastructure environments
while continuing to expand its Smell ID datasets and refine its Smell Language Model ("SLM") through deployment and pilot
first quarter progress reflects a continued transition from validation activities toward broader enterprise-level infrastructure deployment
readiness," said Eddy Tsai, Chairman, President and CEO of Ainos. "We believe the operational milestones achieved during
the quarter has strengthened the foundation for future scalable commercialization of Smell AI - powered by AI Nose."
addition to our progress in semiconductor environments, we are expanding AI Nose deployment into healthcare infrastructure settings,
including hospital utility systems, laboratory environments, HVAC-related monitoring, MRI-related environments, and critical infrastructure
safety applications. We believe this represents an important long-term application category for AI-driven environmental intelligence,
by enabling continuous monitoring, anomaly awareness, and operational stability for hospital operation," Mr. Tsai concluded.
Lee, Chief Financial Officer of Ainos, added, "During the first quarter, we strengthened our balance sheet and liquidity position
through the previously announced NT$90 million (approximately US$2.8 million) financing arrangement while maintaining operating discipline
as we advanced commercialization activities. Reported operating expenses declined approximately 30% year-over-year to approximately US$2.28
during the quarter reflected the Company's ongoing transition toward industrial and infrastructure-focused AI Nose deployments,
which remain in earlier stages of commercialization and validation. We believe our current execution priorities will help support broader
revenue generation opportunities in the second half of 2026," Mr. Lee added.
Quarter 2026 and Recent Operational Highlights
Continued deployment activities associated with the previously announced approximately three-year $2.1 million AI Nose commercial arrangement
in backend semiconductor manufacturing environments, targeting approximately 1400 AI Nose systems
Initiated pilot and validation activities in selected front-end semiconductor environments
Expanded industrial commercialization initiatives through a distribution partnership supporting front-end semiconductor opportunities
Continued robotics integration and pilot activities involving robotic and quadruped systems
Continued development of Smell ID datasets and Smell Language Model capabilities through deployment and pilot activities
Continued optimization of AI Nose's near-threshold sensing and pattern-recognition capabilities through ongoing deployment and
validation activities, supporting earlier identification of environmental anomalies across customer environments
Company believes that enterprise adoption of AI-driven environmental intelligence technologies is typically driven by structured implementation
roadmap with phased validation, infrastructure integration, and staged deployment. Ainos is aligning its commercialization strategy with
these anticipated enterprise adoption patterns as it advances AI Nose across semiconductor, healthcare infrastructure, robotics, and
remains focused on execution, deployment readiness, Smell ID dataset expansion, Smell Language Model development, and strategic commercial
expansion, supporting its long-term objective of advancing AI Nose as a scalable Smell AI platform for real-world infrastructure environments.
Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision
MEMS sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions
and deployment configurations. Smell ID converts analog scent signals into structured, actionable data, while the proprietary Smell Language
Model (SLM) is designed to learn, classify, and contextualize complex scent patterns over time.
upon more than a decade of accumulated scent data and deep medtech expertise, AI Nose is designed to support continuous monitoring, predictive
analysis, and real-time alerts across industrial and manufacturing environments. AI Nose is offered under a SmellTech-as-a-Service architecture,
intended to support ongoing access to scent intelligence, analytics, and AI-driven insights through subscription-based deployment models.
Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell
language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart
factories, and healthcare. The company also develops VELDONA , a low-dose oral interferon targeting rare, autoimmune,
and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory
age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn
statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking
statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends,
which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other
events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking
statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of
important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated
by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur
net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product
development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates
through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain
and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current
and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability
to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section
of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to
risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking
statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes
no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Consolidated Balance Sheets
| March 31, 2026 | December 31, 2025 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 2,841,422 | $ | 417,353 | ||||
| Accounts receivable | 23 | 22 | ||||||
| Inventory, net | 315,643 | 295,565 | ||||||
| Other current assets | 362,527 | 425,859 | ||||||
| Total current assets | 3,519,615 | 1,138,799 | ||||||
| Intangible assets, net | 18,110,834 | 19,226,003 | ||||||
| Property and equipment, net | 290,078 | 343,281 | ||||||
| Other assets | 161,056 | 163,025 | ||||||
| Total assets | $ | 22,081,583 | $ | 20,871,108 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Contract liabilities | $ | 350,000 | $ | 350,000 | ||||
| Convertible notes payable - Related parties - current | 2,000,000 | - | ||||||
| Loan payable to related parties | 2,812,940 | - | ||||||
| Accrued expenses and others current liabilities | 1,183,539 | 728,683 | ||||||
| Total current liabilities | 6,346,479 | 1,078,683 | ||||||
| Convertible notes payable - Related parties - noncurrent | 9,000,000 | 11,000,000 | ||||||
| Other long-term liabilities | 1,043,158 | 1,229,843 | ||||||
| Total liabilities | 16,389,637 | 13,308,526 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity: | ||||||||
| Preferred stock, $0.01 par value; 50,000,000 shares authorized; none issued and outstanding as of March 31, 2026 and December 31, 2025 | - | - | ||||||
| Common stock, $0.01 par value; 300,000,000 shares authorized as of March 31, 2026 and December 31, 2025, 7,266,011 and 6,982,675 shares issued and 6,106,011 and 5,822,675 shares outstanding as of March 31, 2026, and December 31, 2025, respectively | 72,660 | 69,827 | ||||||
| Treasury stock, at cost (1,160,000 shares held as of March 31, 2026 and December 31, 2025) | (1,972,000 | ) | (1,972,000 | ) | ||||
| Additional paid-in capital | 77,833,141 | 77,234,374 | ||||||
| Accumulated deficit | (69,980,128 | ) | (67,520,328 | ) | ||||
| Accumulated other comprehensive loss | (261,727 | ) | (249,291 | ) | ||||
| Total stockholders' equity | 5,691,946 | 7,562,582 | ||||||
| Total liabilities and stockholders' equity | $ | 22,081,583 | $ | 20,871,108 |
Consolidated Statements of Operations
| Three months ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Revenues | $ | 161 | $ | 106,207 | ||||
| Cost of revenues | (763 | ) | (18,233 | ) | ||||
| Gross profit (loss) | (602 | ) | 87,974 | |||||
| Operating expenses: | ||||||||
| Research and development | 1,689,860 | 1,724,084 | ||||||
| Selling, general and administrative | 593,185 | 1,526,761 | ||||||
| Total operating expenses | 2,283,045 | 3,250,845 | ||||||
| Loss from operations | (2,283,647 | ) | (3,162,871 | ) | ||||
| Non-operating (expenses) income, net: | ||||||||
| Interest expense | (176,876 | ) | (180,445 | ) | ||||
| Other income, net | 723 | 57,294 | ||||||
| Total non-operating expenses, net | (176,153 | ) | (123,151 | ) | ||||
| Net loss before income taxes | (2,459,800 | ) | (3,286,022 | ) | ||||
| Provision for income taxes | - | - | ||||||
| Net loss | $ | (2,459,800 | ) | $ | (3,286,022 | ) |